A+AVD versus eBEACOPP in advanced-stage Hodgkin lymphoma.
Publication
, Journal Article
Diehl, LF
Published in: Lancet Haematol
June 2021
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Lancet Haematol
DOI
EISSN
2352-3026
Publication Date
June 2021
Volume
8
Issue
6
Start / End Page
e384 / e386
Location
England
Related Subject Headings
- Vincristine
- Vinblastine
- Humans
- Hodgkin Disease
- Brentuximab Vedotin
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Diehl, L. F. (2021). A+AVD versus eBEACOPP in advanced-stage Hodgkin lymphoma. Lancet Haematol, 8(6), e384–e386. https://doi.org/10.1016/S2352-3026(21)00129-0
Diehl, Louis F. “A+AVD versus eBEACOPP in advanced-stage Hodgkin lymphoma.” Lancet Haematol 8, no. 6 (June 2021): e384–86. https://doi.org/10.1016/S2352-3026(21)00129-0.
Diehl LF. A+AVD versus eBEACOPP in advanced-stage Hodgkin lymphoma. Lancet Haematol. 2021 Jun;8(6):e384–6.
Diehl, Louis F. “A+AVD versus eBEACOPP in advanced-stage Hodgkin lymphoma.” Lancet Haematol, vol. 8, no. 6, June 2021, pp. e384–86. Pubmed, doi:10.1016/S2352-3026(21)00129-0.
Diehl LF. A+AVD versus eBEACOPP in advanced-stage Hodgkin lymphoma. Lancet Haematol. 2021 Jun;8(6):e384–e386.
Published In
Lancet Haematol
DOI
EISSN
2352-3026
Publication Date
June 2021
Volume
8
Issue
6
Start / End Page
e384 / e386
Location
England
Related Subject Headings
- Vincristine
- Vinblastine
- Humans
- Hodgkin Disease
- Brentuximab Vedotin
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology